Arbios gets funding towards artificial liver trial
This article was originally published in Clinica
Arbios Systems has raised $6.61m in a private placement that will enable it to prepare for a phase III trial of its bioartificial liver (BAL), HepatAssist-2. This device is an enhanced version of Circe Biomedical's HepatAssist, the rights to which Arbios reacquired last April (see Clinica No 1105, p 21). It is hoped such technology will support a patient with acute liver failure until either they receive a transplant or their own liver recovers.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.